Immunovant, Inc. (IMVT)Healthcare | Biotechnology | Durham, United States | NasdaqGS
38.70 USD
-1.01
(-2.543%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:50 a.m. EDT
The immediate outlook is driven by a sharp divergence between the company's deteriorating fundamentals and aggressive speculative positioning. While the business faces significant headwinds—negative earnings, a trailing P/E of -16, and a recent year-over-year decline—the options market is screaming for a reversal. The sheer volume of calls at the $30 strike suggests a collective belief that the stock will reclaim lost ground soon, likely fueled by potential catalysts like the IMVT-1402 data mentioned in recent headlines. However, the long-term picture remains murky; the company is burning cash with no dividend to cushion the blow, and the recent price drop indicates the market is currently pricing in substantial risk. This creates a high-risk, high-reward scenario suitable only for traders willing to bet on a turnaround, rather than investors seeking stability. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.125952 |
| AutoARIMA | 0.131273 |
| AutoETS | 0.131278 |
| AutoTheta | 0.136011 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 21.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.279 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.008 |
| Market Cap | 7,945,455,104 |
| Forward P/E | -15.88 |
| Beta | 0.77 |
| Website | https://immunovant.com |
As of July 11, 2026, 2:50 a.m. EDT: Speculators are aggressively positioning for a rebound, evidenced by massive call volume at the $30 strike in September and heavy open interest walls at $30 and $40 across multiple expirations. Conversely, put activity is concentrated deep out-of-the-money (below $20-$25), suggesting a hedge against further downside rather than a bet on a crash. The skew indicates a 'long gamma' setup where traders expect volatility expansion and a move higher, betting on the recovery of the biotech asset.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1360946 |
| Address1 | 1,000 Park Forty Plaza |
| Address2 | Suite 210 |
| All Time High | 53.75 |
| All Time Low | 3.145 |
| Ask | 48.44 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,488,840 |
| Average Daily Volume3 Month | 1,946,672 |
| Average Volume | 1,946,672 |
| Average Volume10Days | 1,488,840 |
| Beta | 0.766 |
| Bid | 27.79 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 4.181 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 38.7 |
| Current Ratio | 9.086 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 39.335 |
| Day Low | 37.53 |
| Debt To Equity | 0.008 |
| Display Name | Immunovant |
| Earnings Call Timestamp End | 1,779,278,400 |
| Earnings Call Timestamp Start | 1,779,278,400 |
| Earnings Timestamp | 1,779,280,200 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -532,492,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.227 |
| Enterprise Value | 7,043,417,088 |
| Eps Current Year | -2.44406 |
| Eps Forward | -2.43636 |
| Eps Trailing Twelve Months | -2.77 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 33.1309 |
| Fifty Day Average Change | 5.5690994 |
| Fifty Day Average Change Percent | 0.16809382 |
| Fifty Two Week Change Percent | 113.60946 |
| Fifty Two Week High | 41.23 |
| Fifty Two Week High Change | -2.5299988 |
| Fifty Two Week High Change Percent | -0.061363056 |
| Fifty Two Week Low | 14.32 |
| Fifty Two Week Low Change | 24.380001 |
| Fifty Two Week Low Change Percent | 1.702514 |
| Fifty Two Week Range | 14.32 - 41.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,123,800,000 |
| Float Shares | 78,738,023 |
| Forward Eps | -2.43636 |
| Forward P E | -15.884353 |
| Free Cashflow | -234,283,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 315 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.56555 |
| Held Percent Institutions | 0.54635 |
| Implied Shares Outstanding | 205,308,917 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. |
| Long Name | Immunovant, Inc. |
| Market | us_market |
| Market Cap | 7,945,455,104 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_592774643 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -505,606,016 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 7,945,455,087 |
| Number Of Analyst Opinions | 17 |
| Open | 39.24 |
| Operating Cashflow | -407,310,016 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 917 410 3120 |
| Pre Market Change | 2.1100006 |
| Pre Market Change Percent | 5.452198 |
| Pre Market Price | 40.81 |
| Pre Market Time | 1,784,023,957 |
| Previous Close | 39.71 |
| Price Eps Current Year | -15.834309 |
| Price Hint | 2 |
| Price To Book | 9.256159 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.677 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -1.01 |
| Regular Market Change Percent | -2.54344 |
| Regular Market Day High | 39.335 |
| Regular Market Day Low | 37.53 |
| Regular Market Day Range | 37.53 - 39.335 |
| Regular Market Open | 39.24 |
| Regular Market Previous Close | 39.71 |
| Regular Market Price | 38.7 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 788,526 |
| Return On Assets | -0.38432997 |
| Return On Equity | -0.6482 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 205,308,917 |
| Shares Percent Shares Out | 0.0876 |
| Shares Short | 17,991,218 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 19,208,923 |
| Short Name | Immunovant, Inc. |
| Short Percent Of Float | 0.1982 |
| Short Ratio | 10.32 |
| Source Interval | 15 |
| State | NC |
| Symbol | IMVT |
| Target High Price | 66.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 46.47059 |
| Target Median Price | 47.0 |
| Total Cash | 902,110,016 |
| Total Cash Per Share | 4.394 |
| Total Debt | 72,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.3326 |
| Two Hundred Day Average Change | 12.367401 |
| Two Hundred Day Average Change Percent | 0.46966124 |
| Type Disp | Equity |
| Volume | 788,526 |
| Website | https://immunovant.com |
| Zip | 27,713 |